{"id":"W2883282832","doi":"10.1111/dom.13470","title":"Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild‐to‐moderate renal impairment","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Health; University of Alberta Hospital; University of Alberta; Alberta Health Services","funders":"Servier; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Novo Nordisk; Valeant Pharmaceuticals International; Sanofi; American Diabetes Association","keywords":"Medicine; Insulin glargine; Type 2 diabetes; Type 1 diabetes; Internal medicine; Continuous glucose monitoring; Diabetes mellitus; Insulin; Endocrinology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007052193,0.00164479,0.007719377,0.00114448,0.0002571506,0.001920919,0.0007561006,0.001783418,0.002692791],"category_scores_gemma":[0.009201841,0.0009517138,0.02284173,0.001320211,0.0005916365,0.0009742889,0.0007403007,0.002503522,0.0002323833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005390676,"about_ca_system_score_gemma":0.0005642846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001970026,"about_ca_topic_score_gemma":0.002802891,"domain_scores_codex":[0.9965113,0.0021502,0.0004950872,0.0004446213,0.0002489965,0.0001497548],"domain_scores_gemma":[0.9947371,0.0037095,0.001027047,0.0002069283,0.0001591117,0.0001602459],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","study_design_scores_codex":[0.218449,0.0003863456,0.008549684,0.05931728,0.6433942,0.000235589,0.0001240745,0.001988291,0.001766159,0.0002807958,0.001157463,0.0643511],"study_design_scores_gemma":[0.06359033,0.01451026,0.02568467,0.004629018,0.8846791,0.0002871306,0.0001069817,0.001050269,0.0007092486,0.001088553,0.003600043,0.00006438534],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1682781,0.8247077,0.001629711,0.000994318,0.001139271,0.0002962966,0.0006863799,0.0001070492,0.002161183],"genre_scores_gemma":[0.8818214,0.1130943,0.001303554,0.001530994,0.0008618117,0.0002478749,0.0004262142,0.00003141155,0.0006825392],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007719377,"threshold_uncertainty_score":0.03729606,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01561011547680057,"score_gpt":0.2655334214507449,"score_spread":0.2499233059739443,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}